Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:10 AM ET 10-Q
Financial Results Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics Q3 2026 Results: Net Loss of $49.4M, Loss Narrows

Cullinan Therapeutics, Inc. reported total assets of $322.6 million as of September 30, 2026, a decrease from $448.4 million at the end of 2025, primarily driven by a reduction in short-term and long-term investments. The company maintains a strong liquidity position with $289.6 million in cash, cash equivalents, and short-term investments to fund its clinical-stage product candidates. Total liabilities remained relatively stable at $41.3 million.

Key figure
Net loss $49.4M
7:08 AM ET 8-K
Financial Results Hemab Therapeutics Holdings, Inc. COAG

Hemab Therapeutics Holdings Financial Results

Hemab Therapeutics reported financial results for the third quarter of 2026 and provided a corporate update on its clinical pipeline. The company transitioned to a late-stage biotech by initiating the SOLARA Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia and dosing the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding.

Term
Q3 2026

“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”

Benny Sørensen, MD, PhD, CEO of Hemab

“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”

Benny Sørensen, MD, PhD, CEO of Hemab
7:07 AM ET 8-K
Financial Results Palladyne AI Corp. PDYN

Palladyne AI Financial Results

Palladyne AI reported record Q3 2026 revenue of $8.6 million, representing 895% year-over-year growth driven by government contracts and its components business. The company raised the low end of its full-year 2026 revenue guidance to $25 million and reported a total backlog of $18.7 million. Management highlighted the successful field evaluation of SwarmOS by the U.S. Army and the commercial launch of the BRAIN FC-1 flight computer.

Term
Q3 2026

“We generated record revenues in the third quarter of $8.6 million, an increase of 895% year over year and up 48% sequentially. Compared to Q2, we saw a 26% increase in revenues associated with our components business, driven in part by our first delivery of our next generation BRAIN FC-1 flight computers. Our revenue from government contracts increased 135% quarter over quarter. Given our current trajectory, we are raising the low end of our full-year revenue guidance to $25 million, while reiterating the top end of $27 million.”

Ben Wolff, President and Chief Executive Officer
7:07 AM ET 8-K
Business Update City Therapeutics, Inc. CTY

City Therapeutics Business Update

City Therapeutics announced the first participant has been dosed in its Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease. The trial is a first-in-human study evaluating the safety, tolerability, and pharmacodynamics of the RNAi therapeutic candidate, with initial data expected in mid-2027.

7:06 AM ET 8-K
Financial Results Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics Financial Results

Cullinan Therapeutics reported third quarter 2026 financial results and provided a corporate update on its T cell engager portfolio. The company ended the quarter with $313.8 million in cash and investments, providing a projected cash runway into 2029. Key upcoming milestones include data readouts for CLN-978 in autoimmune indications and the completion of the zipalertinib NDA submission in November.

Term
Q3 2026

“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have advanced velinotamig into a global study in autoimmune cytopenias and initiated a potentially registrational Phase 2 study of CLN-049 in relapsed and refractory AML.”

Nadim Ahmed, President and CEO of Cullinan Therapeutics

“Looking ahead, we remain focused on strengthening our leadership position in the T cell engager space. This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications and will share updated data for CLN-049 at the ASH Annual Meeting. With multiple upcoming clinical catalysts and regulatory milestones, coupled with our strong balance sheet, we are well positioned to translate this momentum into meaningful progress for patients and long-term value for shareholders.”

Nadim Ahmed, President and CEO of Cullinan Therapeutics
7:06 AM ET 10-Q
Financial Results Boundless Bio, Inc. BOLD

Boundless Bio Q3 2026 Results: Net Loss of $5.36M, Loss Narrows

Boundless Bio, Inc. has entered into a definitive merger agreement with Serapha Bio, Inc., which will result in significant ownership dilution for existing stockholders and a potential reverse stock split. The company remains a clinical-stage biopharmaceutical firm with no revenue, a limited operating history, and expectations of continued significant operating losses as it develops its extrachromosomal DNA (ecDNA) directed therapeutic candidates.

Key figure
Net loss $5.36M
7:06 AM ET 8-K
Financial Results Sionna Therapeutics, Inc. SION

Sionna Therapeutics Financial Results

Sionna Therapeutics reported Q3 2026 financial results and announced plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for its SION-451 and SION-2222 dual combination in Q1 2027. The company ended the quarter with $249.8 million in cash, which is expected to fund operations into the second half of 2029.

Term
Q3 2026

“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination. We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”

Mike Cloonan, President and Chief Executive Officer
7:06 AM ET 10-Q
Financial Results Ovid Therapeutics Inc. OVID

Ovid Therapeutics Q3 2026 Results: Net Loss of $20.8M, Loss Widens

Ovid Therapeutics reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to a $27.1 million loss in the prior year period. The increase in loss was primarily driven by a significant rise in research and development expenses, which grew from $19.0 million to $36.8 million year-over-year.

Key figure
Net loss $20.8M
7:05 AM ET 8-K
Financial Results 908 Devices Inc. MASS

908 Devices Financial Results

908 Devices reported record third-quarter revenue of $19.0 million, a 35% increase year-over-year, driven by strong demand for its FTIR portfolio and the addition of NIRLab revenue. The company achieved a record 308 device shipments in the quarter and raised the low end of its full-year 2026 revenue guidance to a range of $68.5 million to $70.0 million.

Term
Q3 2026

“We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record.”

Kevin J. Knopp, CEO and Co-founder

“Our proven platforms are winning orders across the globe as customers accelerate efforts to modernize their detection capabilities and stay ahead of an evolving threat landscape.”

Kevin J. Knopp, CEO and Co-founder
7:05 AM ET 8-K
Financial Results Upstream Bio, Inc. UPB

Upstream Bio Financial Results

Upstream Bio reported third quarter 2026 financial results, ending the period with $207.4 million in cash and short-term investments. The company is preparing to initiate Phase 3 trials for its lead candidate verekitug in severe asthma and CRSwNP in the first quarter of 2027. Research and development expenses increased to $36.6 million as the company advances its clinical programs and expands its personnel.

Term
Q3 2026

“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved.”

Rand Sutherland, MD, Chief Executive Officer of Upstream Bio

“As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”

Rand Sutherland, MD, Chief Executive Officer of Upstream Bio
7:05 AM ET 8-K
Financial Results Olema Pharmaceuticals, Inc. OLMA

Olema Pharmaceuticals Financial Results

Olema Pharmaceuticals reported a net loss of $73.6 million for the third quarter of 2026, driven by increased clinical trial enrollment costs. The company ended the period with $413.8 million in cash and remains on track to report pivotal Phase 3 OPERA-01 data in the first quarter of 2027.

Term
Q3 2026

“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer.”

Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer

“We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting. With its dual mechanism of action as a complete estrogen receptor antagonist and selective estrogen receptor degrader, optimal pharmacokinetic properties, encouraging clinical profile demonstrated to date, and potential for use both as a monotherapy and in combination with other agents, we believe palazestrant is uniquely positioned to transform the metastatic breast cancer treatment paradigm.”

Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer
7:05 AM ET 8-K
Financial Results Humacyte, Inc. HUMA

Humacyte Financial Results

Humacyte reported Q3 2026 financial results, highlighted by a 151% sequential increase in Symvess revenue to $1.0 million. The company remains on track to file a supplemental Biologics License Application (sBLA) for its ATEV in dialysis access with the FDA in November 2026.

Term
Q3 2026

“During our third quarter, we continued the transformation of our Symvess commercial program in vascular injury repair, doubling revenue over our second quarter and significantly increasing the number of hospitals ordering Symvess.”

Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte

“Execution of our revamped commercial program for Symvess generated significant momentum during the third quarter. Symvess sales revenue for the third quarter was $1.0 million, more than double our results for the second quarter, and achieved the goal we set for the period.”

Jim Mercadante, Chief Commercial Officer of Humacyte
7:04 AM ET 10-Q
Financial Results Protalix BioTherapeutics, Inc. PLX

Protalix BioTherapeutics Q3 2026 Results: Net Income $3.96M, Up 68.2% YoY

Protalix BioTherapeutics reported a significant turnaround for the nine months ended September 30, 2026, with net income of $26.1 million compared to a net loss of $1.1 million in the prior year period. This growth was driven by a substantial increase in total revenue to $75.6 million, primarily due to a surge in license and R&D services revenue.

Key figure
Net income $3.96M · +68.2% YoY
7:03 AM ET 8-K
Financial Results Ovid Therapeutics Inc. OVID

Ovid Therapeutics Financial Results

Ovid Therapeutics reported third quarter 2026 financial results, ending the period with $161.4 million in cash and marketable securities. The company highlighted clinical progress for OV329 in focal epilepsy and the initiation of a Phase 1 study for OV4071, with a projected financial runway extending into 2029.

Term
Q3 2026

“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline. We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor.”

Meg Alexander, President and Chief Executive Officer
7:02 AM ET 8-K
Financial Results D-Wave Quantum Inc. QBTS

D-Wave Quantum Financial Results

D-Wave Quantum reported Q3 2026 revenue of $4.5 million, a 21% year-over-year increase, driven by growing commercial interest in its dual-platform quantum approach. The company highlighted a 611% surge in year-to-date bookings to $37.4 million and the execution of a definitive agreement for up to $100 million in U.S. CHIPS Act funding to support next-generation system development.

Term
Q3 2026

“From Seoul to Como to Washington, we are seeing growing interest in D-Wave’s differentiated dual-platform approach and a determination to put our quantum computing technology to work today. Our triple-digit increase in year-to-date bookings and robust pipeline reinforce our confidence in the opportunity ahead. We are expanding our commercial reach and executing on both our annealing and gate-model roadmaps with a clear objective: to lead this industry in technical and scientific innovation, measurable customer value and growth.”

Dr. Alan Baratz, CEO of D-Wave
7:02 AM ET 8-K
Financial Results Opus Genetics, Inc. IRD

Opus Genetics Financial Results

Opus Genetics reported financial results for the third quarter of 2026, highlighting a cash runway extending into 2029. The company achieved several clinical milestones, including full enrollment of its OPGx-LCA5 Phase 3 trial and FDA clearance of the IND for OPGx-RDH12. Additionally, the FDA approval of RYZUMVI for presbyopia triggered a regulatory milestone payment to the company.

Term
Q3 2026

“The last several months have marked a period of tremendous advancement for our leading gene therapy programs. Positive Cohort 1 data from our Phase 1/2 trial of OPGx-BEST1 provide important evidence of its potential to improve both visual function and retinal structure in patients with BEST1-related retinal disease.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics

“The FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia marks the second FDA-approved indication for RYZUMVI®, demonstrating the capabilities of our clinical and regulatory teams. With our cash runway into 2029, we remain focused on bringing potentially transformative gene therapies to patients with rare inherited retinal diseases.”

George Magrath, M.D., Chief Executive Officer of Opus Genetics
7:01 AM ET 8-K
M&A Deal SUNation Energy, Inc. SUNE

SUNation Energy M&A Deal with Suniva, Inc.

SUNation Energy provided a status update on its pending reverse merger with Suniva, Inc., noting that Suniva has commenced construction on a new 4.5 GW solar cell manufacturing facility in South Carolina. The $600 million expansion project is expected to increase the combined company's total U.S. manufacturing capacity to 5.5 GW by 2028. The merger, originally announced in June 2026, will result in Suniva becoming a wholly owned subsidiary of SUNation.

Counterparty
Suniva, Inc.
7:01 AM ET 8-K
Financial Results Chicago Atlantic Real Estate Finance, Inc. REFI

Chicago Atlantic Real Estate Finance Financial Results

Chicago Atlantic Real Estate Finance reported third quarter 2026 financial results, including net income of $6.4 million and distributable earnings of $0.49 per diluted share. The company's total loan principal outstanding grew to $527.7 million, supported by $88.0 million in principal advances during the quarter. Management highlighted the strategic Koach transaction and disciplined underwriting despite a challenging macroeconomic environment.

Term
Q3 2026

“Chicago Atlantic delivered distributable earnings of $0.49 per diluted weighted average share for the third quarter of 2026, despite a challenging macroeconomic environment and heightened uncertainty across both the regulatory landscape and the mortgage REIT sector.”

Peter Sack, Co-Chief Executive Officer

“We believe the deliberate, strategic decisions we have made, such as the Koach transaction in the third quarter, position the Company for long-term success.”

Peter Sack, Co-Chief Executive Officer
7:01 AM ET 8-K
Stock Buyback Enova International, Inc. ENVA

Enova International Announces $500M Stock Buyback

Enova International's Board of Directors authorized a new $500 million share repurchase program, the largest in the company's history. This program replaces a previous $400 million authorization and is scheduled to remain in place until June 30, 2028.

Value
$500M
Term
through June 2028
7:01 AM ET 10-Q
Financial Results Chicago Atlantic Real Estate Finance, Inc. REFI

Chicago Atlantic Real Estate Finance Q3 2026 Results: Net Income $6.43M, Down 28.0% YoY

For the nine months ended September 30, 2026, Chicago Atlantic Real Estate Finance reported net income of $18.7 million, a decrease from $27.9 million in the prior year period, primarily driven by a significant increase in the provision for current expected credit losses. Total assets grew to $468.2 million, supported by an increase in loans held for investment and the issuance of common stock in exchange for notes.

Key figure
Net income $6.43M · -28.0% YoY
7:01 AM ET 8-K
Financial Results Liquidia Corp LQDA

Liquidia Financial Results

Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.

Term
Q3 2026

“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer
7:01 AM ET 8-K
Investor Presentation Harvard Bioscience Inc HBIO

Harvard Bioscience Investor Presentation

Harvard Bioscience filed its updated corporate slide presentation for November 2026 to provide the investment community with updates and summaries of its business operations. The presentation includes forward-looking information regarding expected financial performance, including adjusted EBITDA margins and the introduction of new products aimed at accelerating drug development.

7:01 AM ET 8-K
Financial Results Janus International Group, Inc. JBI

Janus International Group Financial Results

Janus International Group reported third quarter 2026 revenues of $213.1 million, a 2.8% decrease year-over-year, and a net loss of $13.3 million. The company updated its full-year 2026 revenue guidance to a range of $855 million to $865 million and noted it repurchased 5.0 million shares during the quarter for $25.3 million.

Term
Q3 2026

“Market conditions remained dynamic during the third quarter, with activity levels softer than anticipated. While we continue to believe the long-term fundamentals supporting our business remain intact, we are taking actions to align our operating structure with current demand, improve efficiency, and strengthen the business.”

Ramey Jackson, Chief Executive Officer
7:00 AM ET 8-K
Financial Results Harvard Bioscience Inc HBIO

Harvard Bioscience Financial Results

Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.

Term
Q3 2026

“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”

John Duke, President and Chief Executive Officer
6:56 AM ET 10-Q
Financial Results Cellectar Biosciences, Inc. CLRB

Cellectar Biosciences Q3 2026 Results: Net Loss of $7.97M, Loss Widens

Cellectar Biosciences reported a net loss of $20.6 million for the nine months ended September 30, 2026, as it continues to invest in its phospholipid drug conjugate platform. The company significantly improved its cash position to $24.6 million through the issuance of common stock and warrants, though management notes a continued dependence on outside capital to fund operations.

Key figure
Net loss $7.97M
6:55 AM ET 6-K
Financial Results IHS Holding Ltd IHS

IHS Holding Q3 2026 Results: Net Loss of $8.2M

IHS Holding Ltd is navigating significant macroeconomic risks, including Nigerian Naira volatility and potential impacts from a merger agreement with MTN Group Limited. The company continues to manage its debt profile through various senior notes while executing its 'Carbon Reduction Roadmap' to reduce emissions intensity by 50% by 2030.

Key figure
Net loss $8.2M
6:54 AM ET 8-K
Financial Results Protalix BioTherapeutics, Inc. PLX

Protalix BioTherapeutics Financial Results

Protalix BioTherapeutics reported Q3 2026 financial results with total year-to-date revenues reaching $75.6 million, a significant increase from $43.6 million in the prior year. The company reported quarterly net income of $4.0 million and reaffirmed its full-year 2026 revenue guidance of $78.0 million to $83.0 million. Management highlighted the ongoing Phase 2 RELEASE study for PRX-115 in uncontrolled gout, with top-line results expected in the second half of 2027.

Term
Q3 2026

“We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial strength which supports our ability to execute our strategy and advance our key priorities.”

Dror Bashan, President and Chief Executive Officer

“We end the quarter with cash and deposits of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need and represents a blockbuster uricase market opportunity.”

Dror Bashan, President and Chief Executive Officer
6:51 AM ET 10-Q
Financial Results WhiteFiber, Inc. WYFI

WhiteFiber Q3 2026 Results: Net Loss of $101M, Loss Widens

WhiteFiber, Inc. reported a significant revenue increase to $74.8 million for the nine months ended September 30, 2026, driven by growth in cloud and colocation services. However, the company incurred a substantial net loss of $128.5 million, primarily due to an $80.8 million induced conversion expense related to its convertible notes.

Key figure
Net loss $101M
6:51 AM ET 8-K
Financial Results Sally Beauty Holdings, Inc. SBH

Sally Beauty Holdings Financial Results

Sally Beauty Holdings reported fourth quarter and full year 2026 results, featuring a 0.6% increase in Q4 consolidated net sales to $953 million and 22% growth in GAAP diluted EPS. The company generated $323 million in full-year operating cash flow and provided fiscal 2027 guidance in line with its long-term financial algorithm.

Term
Q4 2026

“We finished fiscal 2026 with positive momentum, delivering fourth quarter sales, operating earnings and double-digit adjusted EPS growth. Throughout the year, we strengthened our business through disciplined execution, new customer growth, digital and omnichannel expansion, product innovation, and continued advancement of our long-term growth agenda.”

Denise Paulonis, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.